Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
AVEO Oncology logo — Committed to delivering medicines that provide a better life...

AVEO Oncology

Committed to delivering medicines that provide a better life for patients with cancer.

Founded 2001 United States Boston, United States 197 employees Post-IPO Equity Biotechnology, Health Care +2

General Information

Company Name AVEO Oncology
Founded Year 2001
Location United States Boston, United States
Founders / Decision Makers
Team member Team member
Employees 197
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with AVEO Oncology. To contact AVEO Oncology, visit aveooncology.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AVEO Oncology compare?

A PDF of AVEO Oncology and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AVEO Oncology soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AVEO Oncology

AVEO Oncology is a commercial-stage, oncology-focused biopharmaceutical company established in 2001. The company's slogan, "Committed to delivering medicines that provide a better life for patients with cancer," reflects its dedication to improving the lives of cancer patients. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. Furthermore, AVEO is actively involved in developing FOTIVDA in immuno-oncology combinations in RCC and other indications, in addition to having other investigational programs in clinical development. Notably, AVEO is committed to fostering diversity, equity, and inclusion within the company. The most recent investment in AVEO Oncology was a Post-IPO Equity investment on 22 March 2021. Although details about the specific investors are not provided, the company's focus on oncology and its track record in delivering medicines for cancer patients underscore its appeal to potential venture capital interests.

Business keywords: oncology-focused biopharmaceutical, cancer therapeutics, drug development, clinical development, immuno-oncology combinations, proprietary cancer biology platform, targeted cancer therapies, biopharmaceutical company, diversity and inclusion, late-stage biopharmaceutical, commercial-stage, integrated cancer biology, novel cancer therapies, collaborations with pharmaceutical companies

Funding Rounds & Investors (14)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed -
22 Mar 2021
Post IPO Debt Undisclosed -
10 Aug 2020
Post IPO Equity Undisclosed -
15 Jun 2020
Post IPO Equity Undisclosed -
28 Mar 2017
Post IPO Equity Undisclosed -
13 May 2016
Post IPO Equity Undisclosed -
01 Jan 2016
Post IPO Equity Undisclosed -
16 Jan 2013
Post IPO Equity Undisclosed -
14 Jun 2011
Post IPO Equity Undisclosed -
03 Nov 2010
Post IPO Equity Undisclosed -
28 May 2010

View All 14 Funding Rounds

AVEO Oncology Alternatives & Competitors

View All Alternatives
AVEO Oncology vs
Kura Oncology, Inc.
Kura Oncology, Inc. United States

Our mission is to realize the promise of precision medicines to help patients with cancer lead bette...

315 employees
Biotechnology, Pharmaceutical
Compare AVEO Oncology vs Kura Oncology, Inc.
AVEO Oncology vs
Tango Therapeutics
Tango Therapeutics United States

Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medic...

Post-IPO Equity
182 employees
Biotechnology, Health Care
AVEO Oncology vs
Onconova Therapeutics
Onconova Therapeutics United States

Onconova is focused on discovering and developing novel products for patients with cancer.

Post-IPO Equity
20 employees
Biopharma, Biotechnology
Also compare with: AVEO Oncology vs Day One Biopharmaceuticals Day One Biopharmaceuticals View all alternatives

FAQ About AVEO Oncology

Committed to delivering medicines that provide a better life for patients with cancer.
AVEO Oncology was founded in 2001.
AVEO Oncology is headquartered in Boston, United States.
AVEO Oncology operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on oncology-focused biopharmaceutical, cancer therapeutics, drug development and clinical development.
AVEO Oncology has approximately 197 employees.
AVEO Oncology has completed 14 funding rounds. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to AVEO Oncology include Kura Oncology, Inc., Tango Therapeutics, Onconova Therapeutics, Lisata Therapeutics, Inc., Apollomics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AVEO Oncology and Kura Oncology, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AVEO Oncology, https://bouncewatch.com/company/aveo-oncology, updated 7 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout